嗅沟脑膜瘤的分子特征与临床相关性:多中心研究
该多中心研究对123例嗅沟脑膜瘤样本进行靶向下一代测序和全基因组测序,分析已知脑膜瘤驱动基因突变与临床及影像特征的关系。结果显示86.2%患者携带已知驱动突变,SMO突变肿瘤体积显著大于AKT1和TRAF7/KLF4突变肿瘤,且SMO突变患者无进展生存期显著缩短。
要点
- 70%嗅沟脑膜瘤携带SMO、AKT1或PIK3CA突变,支持分子分型指导个体化治疗。
- SMO突变肿瘤体积显著大于AKT1和TRAF7/KLF4突变肿瘤。
- SMO突变患者无进展生存期显著短于SMO野生型患者。
核心结论
- 70%嗅沟脑膜瘤携带SMO、AKT1和PIK3CA突变,影响肿瘤行为、症状和结局,支持分子分型用于个体化治疗。
研究设计与样本
- 多中心回顾性研究,对4个国际机构的123例嗅沟脑膜瘤样本进行靶向下一代测序和全基因组测序,并与临床及影像特征比较。
主要发现
- 已知驱动突变见于86.2%(106例)患者,最常见为SMO L412F/W535L和AKT1 E17K各36例(29.3%),PIK3CA/PIK3R1 19例(15.4%),单纯TRAF7 7例(5.7%),POLR2A Q403K 4例(3.3%),TRAF7/KLF4 K409Q 3例(2.4%),17例(13.8%)未检出已知驱动突变。
- AKT1突变患者最年轻(中位年龄51岁,范围30-87岁),单纯TRAF7突变患者最年长(中位66岁,范围28-76岁)。
- SMO突变肿瘤中位体积19.5 cm3,显著大于AKT1突变(中位7.5 cm3,p=0.021)和TRAF7/KLF4突变(中位4.9 cm3,p=0.002)肿瘤。
- 蝶骨平台肿瘤相关骨质增生常见(58.5%),以PIK3CA/PIK3R1、SMO和野生型组居多(分别为73.7%、72.2%、70.6%),AKT1突变组显著较低(25%)(p<0.001)。
- SMO突变患者平均无进展生存期92.0个月(95%CI 70.1-113.9个月),显著短于SMO野生型的158.2个月(95%CI 134.9-181.5个月)(p=0.004)。
关键数值与推荐
- 已知驱动突变检出率86.2%(106/123例),其中SMO和AKT1突变各占29.3%(36例)。
- SMO突变肿瘤中位体积19.5 cm3,AKT1突变7.5 cm3(p=0.021),TRAF7/KLF4突变4.9 cm3(p=0.002)。
- SMO突变患者平均PFS 92.0个月(95%CI 70.1-113.9),SMO野生型158.2个月(95%CI 134.9-181.5)(p=0.004)。
临床怎么用
- 对嗅沟脑膜瘤可考虑分子检测以识别SMO、AKT1、PIK3CA等驱动突变,辅助预后判断和个体化治疗决策。
- SMO突变嗅沟脑膜瘤体积较大且PFS较短,术后可能受益于辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the relationship between the clinical and radiological characteristics of olfactory groove meningiomas (OGMs) and their molecular profiles. METHODS: The authors performed targeted next-generation and whole-genome sequencing in 123 OGM samples collected from 4 international institutions, focusing on known meningioma-driver genes. They compared the molecular data with the clinical and radiographic features of the tumors. Patient and tumor data, including age, sex, radiological features, and overall survival, were retrospectively collected and analyzed. RESULTS: The study cohort comprised 90 females (73%) and 33 males (27%), with a median age at diagnosis of 57 years (range 25-87 years). The majority of tumors (88.6%, n = 109) were classified as WHO grade I meningioma. Known driver mutations were found in 86.2% of patients (n = 106), with the most common mutations found in the SMOL412F/W535L and AKT1E17K genes, each present in 36 cases (29.3%), followed by mutations in PIK3CA/PIK3R1 (19 cases, 15.4%; 14 PIK3CA and 5 PIK3R1), TRAF7 alone (7 cases, 5.7%), POLR2AQ403K (4 cases, 3.3%), and TRAF7/KLF4K409Q (3 cases, 2.4%), while 17 patients (13.8%) did not harbor known meningioma driver mutations (wildtype group). Within molecular subgroups, patients with AKT1 mutations were the youngest (median age 51 years, range 30-87 years) and patients with TRAF7-only mutations were the oldest (median 66 years, range 28-76 years). The median tumor volume at diagnosis was 18.04 cm3. SMO-mutant tumors were significantly larger (median volume 19.5 cm3) than both AKT1-mutant (median 7.5 cm3, p = 0.021) and TRAF7/KLF4-mutant (median 4.9 cm3, p = 0.002) tumors. Tumor-associated hyperostosis of the sphenoid planum was common (58.5%), led by PIK3CA/PIK3R1, SMO, and wildtype groups (73.7%, 72.2%, and 70.6%, respectively), compared with a notably lower rate in AKT1-mutant tumors (25%) (p < 0.001). Tumor invasion of the ethmoid sinuses occurred most frequently in the TRAF7-only mutant OGMs (42.9%), followed by PIK3CA/PIK3R1-mutant (31.6%) and wildtype (23.5%) OGMs. The mean progression-free survival (PFS) was 144.4 months (95% CI 123.8-165 months). Patients with SMO-mutant OGMs exhibited a significantly shorter mean PFS of 92.0 months (95% CI 70.1-113.9 months) compared with 158.2 months (95% CI 134.9-181.5 months) for SMO-wildtype OGMs (p = 0.004), identifying a tumor type that might benefit from adjuvant treatment after resection. CONCLUSIONS: This study revealed that 70% of OGMs harbor SMO, AKT1, and PIK3CA mutations, influencing tumor behavior, symptoms, and outcomes, supporting molecular profiling for personalized treatment in OGM management.
引用
- Alkhatib M, Hua L, Beyer F, et al. Molecular landscape and clinical correlates of olfactory groove meningiomas: a multi-institutional study. J Neurosurg. 2025. PMID: 40911921. doi:10.3171/2025.4.JNS242619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。